摘要
目的:观察紫杉醇联合表阿霉素治疗晚期乳腺癌的临床疗效及不良反应。方法:25例均有组织病理学或细胞学诊断及可评价客观指标。采用紫杉醇175mg/m^2 d1,静脉滴注3小时,用紫杉醇前12小时、6小时分别口服地塞米松20mg,给药前30分钟给予苯海拉明50mg口服从西米替丁300mg静脉滴注。表阿霉素40mg/m^2 d1、d2化疗。21天为一周期,2个周期评价疗效。结果:CR 4例,PH 13例,SD 5例,PD 3例,有效率 68.0％。不良反应主要为白细胞减少,Ⅲ度占 36.0％,Ⅳ度占 28.0％;脱发 Ⅱ度占 48.0％,Ⅲ度占 16.0％;腹泻Ⅱ度占 32.0％,Ⅲ度占16.0％;结论:紫杉醇联合表阿霉素治疗晚期乳腺癌有效率较高,不良反应可耐受。
Objective:To evaluate the curative effect and loxicily of combination chemotherapy with paclitaxel plus Epirubicin in the treatment of advanced breast cancer. Methods; Twenty-five pathologically and cytologically proved case of breast cancer were treated with intravenous infusion of paclitaxed 175 mg/m2 3-hour on the first day,and oral dexamethasome 20mg was given at 12-hour and 6-hour before paclitaxed therapy and oral diphenphdramine 50mg and intravenous infusion of cimitidine 30mg was given at half an hour before Paclitaxel therapy. Epirubicin was given at the dosage of 40mg iv on d1 - d2. each cycle was 21 days and the clinical response was assessed after two cycles. Results: It showed that CR 4,PK 13 , SD 5 , PD 3 Case with an overall effective rate was 68. 0% . the main side effects included Neutropenia, Ⅲ degree 36. 0% , Ⅳ degree 28. 0% , respectively ,alopenia Ⅱ degree 48. 0% , Ⅲ degree 16. 0% , Diarrhea: Ⅱ degree 32. 0% , Ⅲ degree 6. 0% . Conclusion: Paclitaxel plus Epirubicin is effective for advanced breast cancer and toxicities are well tolerated.
出处
《临床肿瘤学杂志》
CAS
2003年第5期345-347,共3页
Chinese Clinical Oncology
